Quality Assistance achieves its 2015 goal of 500 innovative drugs
Since 2015, our team has contributed to the development of 500 innovative drugs, some of which are now on the market.
These 500 new therapeutic molecules are involved in the treatment or prevention of chronic, debilitating, rare or fatal diseases, including many types of cancer, endocrine diseases, neurodegenerative disease (Alzheimer’s, Parkinson’s), SARS-CoV-2, autoimmune diseases, inflammatory diseases, metabolic diseases, or even AIDS.
Accelerate the marketing of tomorrow's drug
Since 1982, with our experience, reliability and scientific, organisational and financial stability, we have become a true European benchmark as much for the large pharmaceutical companies as for biotech start-ups. We supports you during the development phases of new medicines such as immunotherapy, mRNA, conjugated antibodies, new chemical entities, oligonucleotides, nanomedicines, vaccines, cell and gene therapies.
Nathalie Draux adds « Our role is essential. Our clients innovate and trust us to take care in bringing their innovations to market with them. Our responsibility to them, and to all the patients concerned, is to be relentlessly aligned with our values of respect, commitment and excellence, throughout the management and co-development of their projects, in order to accelerate the marketing of the drugs of tomorrow. »
From a financial point of view, our company has accumulated years of record performance with 10% of average annual growth over 5 years and closed 2020 with a turnover of 23.1 million euros with 78% resulting from exports. In order to continue to support the innovation of our clients as well as our internal R&D, we continue to invest in order to grow our operating site located in Donstiennes (Belgium). Our extension project will allow the company to both accelerate the marketing of new treatments and medicines and to support the employment of highly qualified personnel.